LignaMed, LLC, is biotechnology company developing breakthrough treatments for asthma, organ transplant viability and fibrosis. Lead candidate LGM2605 is a novel small molecule synthetic lignan with anti-inflammatory and antioxidant properties. LignaMed holds exclusive licenses to the patents for LGM2605 from The Trustees of the University of Pennsylvania and The Scripps Institute.
| Website | http://www.lignamed.com |
| Revenue | $3 million |
| Employees | View employees |
| Founded | 2013 |
| Address | 3675 Market St Ste 200, Philadelphia, Pennsylvania 19104, US |
| Phone | +1 610-631-1612 |
| Industry | Business Services General, Other Pharmaceuticals and Biotechnology, Business Services, Other Healthcare |
| Competitors | Oracle Health Information, McKesson, Epic, athenahealth, Landin Ofshore, eClinicalWorks, NextGen Healthcare, CureMD, Visier Inc., CareCentric +40 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541714 Companies |
Looking for a particular LignaMed employee's phone or email?
LignaMed Questions
The LignaMed annual revenue was $3 million in 2026.
LignaMed is based in Philadelphia, Pennsylvania.
The NAICS codes for LignaMed are [541, 54171, 54, 5417, 541714].
The SIC codes for LignaMed are [873, 87].
